BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Janssen-Cilag International NV (JNJ) Release: CHMP Announces Positive Opinion For REZOLSTA™, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat 9/29/2014 8:49:54 AM
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014 11:23:27 AM
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014 11:21:55 AM
Janssen-Cilag International NV (JNJ) Release: Post-Hoc Analysis Shows Treatment With INVOKANA® (Canagliflozin) Reduces Both Hba1c And Body Weight In Most Patients With Type 2 Diabetes Mellitus On A Background Of Metformin 9/17/2014 11:20:32 AM
Janssen-Cilag International NV (JNJ) Supports The TeamBG Cycle Tour Raising Awareness Of Diabetes 9/10/2014 11:59:23 AM
Janssen-Cilag International NV (JNJ) Submits EU Marketing Application For VELCADE® (Bortezomib) In Mantle Cell Lymphoma 6/27/2014 10:24:45 AM
Janssen-Cilag International NV (JNJ) Release: OLYSIO™ (Simeprevir) Receives Marketing Authorization In The European Union For The Treatment Of Adults With Hepatitis C Genotype 1 And 4 Infection 5/16/2014 8:58:39 AM
Janssen-Cilag International NV (JNJ) Release: VOKANAMET® (Canagliflozin And Immediate Release Metformin Hydrochloride Fixed Dose Combination) Approved In The European Union For Treatment Of Adults With Type 2 Diabetes [1] 4/25/2014 9:51:08 AM
Janssen-Cilag International NV (JNJ) Release: VOKANAMET™ (Canagliflozin And Metformin Fixed Dose Combination) Receives Positive CHMP Opinion Recommending Approval In The European Union For The Treatment Of Adults With Type 2 Diabetes[1] 2/21/2014 8:45:33 AM
Janssen-Cilag International NV (JNJ)'s INVOKANA™ Wins Approval In The EU For Type 2 Diabetes Patients 11/22/2013 6:25:43 AM
1234